# AEON (AEON Biopharma, Inc.) - SEC EDGAR Financial Statements

> AEON Biopharma, Inc. reported $14.13M in total assets and a net loss of $47.62M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/AEON
- Markdown: https://convexityos.com/fundamentals/AEON.md
- SEC CIK: 0001837607
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:07 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001837607&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$21.85M | Operating profit |
| Net Income | FY 2025 | -$47.62M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.53 | Split-adjusted |
| Free Cash Flow | FY 2025 | -$17.31M | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $11.42M | Total debt: $1.13M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| Research & Development | $4.09M | $14.18M | $34.75M | -- |
| Selling, General & Admin | $12.21M | $13.64M | $13.68M | -- |
| Total Operating Expenses | $12.80M | -$72.98M | $48.43M | -- |
| **Operating Income** | -$12.80M | $72.98M | -$48.43M | -$1.94M |
| **EBITDA** | -$12.72M | $73.08M | -$48.36M | -- |
| Interest Income | -- | -- | $3.71M | $80K |
| Income Before Tax | -$39.22M | $42.01M | -$52.56M | $8.20M |
| Income Tax Expense | $0 | $0 | $0 | -- |
| **Net Income** | -$39.22M | $42.01M | -$52.56M | $8.20M |
| Basic EPS | -$3.95 | $77.74 | -$27.34 | -- |
| **Diluted EPS** | -$3.95 | $72.93 | -$27.34 | -- |
| Basic Shares Outstanding | 9.9M | 540.4K | 1.9M | -- |
| Diluted Shares Outstanding | 9.9M | 575.9K | 1.9M | -- |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.51M | $2.94M | $2.03M | $1.61M | $597K | $1.06M | $825K | $3.04M |
| Selling, General & Admin | $2.99M | $2.99M | $3.90M | $3.89M | $1.93M | $3.26M | $3.12M | $2.63M |
| Total Operating Expenses | $4.48M | $5.92M | $5.93M | $5.51M | $2.49M | $4.34M | $462K | $2.32M |
| **Operating Income** | -$4.48M | -$5.92M | -$5.93M | -$5.51M | -$2.49M | -$4.34M | -$462K | -$2.32M |
| **EBITDA** | -$4.47M | -$5.90M | -$5.91M | -$5.49M | -$2.47M | -$4.32M | -$443K | -$2.30M |
| Income Before Tax | $2.46M | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M |
| **Net Income** | $2.46M | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M |
| Basic EPS | $0.01 | -$0.02 | -$0.29 | -- | -$0.39 | -$0.60 | $2.28 | -- |
| **Diluted EPS** | $0.01 | -$0.02 | -$0.29 | -- | -$0.39 | -$0.60 | $2.28 | -- |
| Basic Shares Outstanding | 90.0M | 50.5M | 40.6M | -- | 11.6M | 11.1M | 4.0M | -- |
| Diluted Shares Outstanding | 90.0M | 50.5M | 40.6M | -- | 11.6M | 11.1M | 4.0M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $3.01M | $13K | $5.16M | $9.75M | $497K | -- |
| **Cash & Short-Term Investments** | $3.01M | $13K | $5.16M | $9.75M | $497K | -- |
| **Total Current Assets** | $3.40M | $1.59M | $6.22M | $9.84M | $835K | $81K |
| Property, Plant & Equipment, Net | $162K | $235K | $332K | $431K | -- | -- |
| Other Non-Current Assets | $948K | $29K | $29K | $34K | -- | -- |
| **Total Non-Current Assets** | $2.16M | $1.55M | $623K | $940K | $276.1M | $0 |
| **Total Assets** | $5.56M | $3.14M | $6.84M | $10.78M | $276.9M | $81K |
| Accounts Payable | $942K | $5.91M | $3.39M | $7.80M | -- | -- |
| **Total Current Liabilities** | $6.90M | $14.15M | $13.05M | $82.57M | $835K | $60K |
| **Total Non-Current Liabilities** | $53.69M | $17.56M | $146.8M | $60.67M | $17.04M | $0 |
| **Total Liabilities** | $60.59M | $31.71M | $159.9M | $143.2M | $17.88M | $60K |
| **Total Debt (incl. Leases)** | $1.15M | $1.27M | $278K | $499K | -- | -- |
| Common Stock | $9.0K | $4.0K | $4.0K | $14K | -- | -- |
| Retained Earnings | -$470.8M | -$431.6M | -$473.6M | -$474.8M | -$16.96M | -$3.6K |
| **Total Stockholders' Equity** | -$55.03M | -$28.57M | -$153.0M | -$287.5M | -$16.93M | $21K |
| Total Equity | -$55.03M | -$28.57M | -$153.0M | -$270.4M | -$223.8M | $21K |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $11.42M | $3.43M | $6.24M | $3.01M | $5.93M | $8.44M | $10.45M | $13K |
| **Cash & Short-Term Investments** | $11.42M | $3.43M | $6.24M | $3.01M | $5.93M | $8.44M | $10.45M | $13K |
| **Total Current Assets** | $12.56M | $3.99M | $6.62M | $3.40M | $7.41M | $10.26M | $12.32M | $1.59M |
| Property, Plant & Equipment, Net | $58K | $123K | $142K | $162K | $181K | $200K | $220K | $235K |
| Other Non-Current Assets | $710K | $863K | $871K | $948K | $29K | $29K | $29K | $29K |
| **Total Non-Current Assets** | $1.57M | $1.92M | $2.00M | $2.16M | $1.32M | $1.40M | $1.48M | $1.55M |
| **Total Assets** | $14.13M | $5.91M | $8.63M | $5.56M | $8.73M | $11.66M | $13.80M | $3.14M |
| Accounts Payable | $981K | $2.70M | $1.48M | $942K | $2.52M | $3.91M | $2.44M | $5.91M |
| **Total Current Liabilities** | $4.57M | $7.34M | $6.67M | $6.90M | $8.23M | $9.13M | $8.64M | $14.15M |
| Other Non-Current Liabilities | $22K | $23K | -- | -- | -- | -- | -- | -- |
| **Total Non-Current Liabilities** | $7.17M | $13.93M | $18.71M | $53.69M | $20.38M | $18.39M | $16.48M | $17.56M |
| **Total Liabilities** | $11.74M | $21.27M | $25.38M | $60.59M | $28.61M | $27.51M | $25.12M | $31.71M |
| **Total Debt (incl. Leases)** | $1.13M | $1.02M | $1.08M | $1.15M | $1.20M | $1.26M | $1.28M | $1.27M |
| Common Stock | $14K | $10K | $10K | $9.0K | $9.0K | $9.0K | $9.0K | $4.0K |
| Retained Earnings | -$481.3M | -$483.8M | -$482.6M | -$470.8M | -$433.7M | -$429.1M | -$422.5M | -$431.6M |
| **Total Stockholders' Equity** | $2.39M | -$15.36M | -$16.75M | -$55.03M | -$19.87M | -$15.85M | -$11.32M | -$28.57M |
| Total Equity | $2.39M | -$15.36M | -$16.75M | -$55.03M | -$19.87M | -$15.85M | -$11.32M | -$28.57M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| Net Income | -$39.22M | $42.01M | -$52.56M | $8.20M |
| Depreciation & Amortization | $78K | $97K | $68K | -- |
| Stock-Based Compensation | $5.32M | $6.25M | $5.89M | -- |
| Change in Payables | -$4.97M | $2.52M | $6.61M | -- |
| **Operating Cash Flow** | -$17.31M | -$20.29M | -$35.58M | -$1.49M |
| Capital Expenditure | -$4.0K | -- | -$306K | -- |
| **Free Cash Flow** | -$17.31M | -- | -$35.89M | -- |
| **Investing Cash Flow** | -$4.0K | -- | -$306K | -$276.0M |
| Common Stock Issued | -- | $147K | -- | $270.5M |
| **Financing Cash Flow** | $20.30M | $15.15M | $40.51M | $278.0M |
| **Net Change in Cash** | $2.99M | -$5.14M | $4.62M | $497K |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $2.46M | -$1.16M | -$11.79M | -$37.14M | -$4.54M | -$6.64M | $9.10M | $2.08M |
| Depreciation & Amortization | $15K | $20K | $19K | $20K | $19K | $20K | $19K | $23K |
| Stock-Based Compensation | $1.56M | $1.66M | $1.93M | $1.59M | $414K | $1.58M | $1.73M | $1.34M |
| Change in Payables | -$1.72M | $1.22M | $539K | -$1.58M | -$1.38M | $1.47M | -$3.47M | $1.28M |
| **Operating Cash Flow** | -$5.72M | -$3.70M | -$2.64M | -$4.71M | -$2.60M | -$2.09M | -$7.91M | -$621K |
| Capital Expenditure | -- | -- | -- | $0 | $0 | $0 | -$4.0K | -- |
| **Free Cash Flow** | -- | -- | -- | -$4.71M | -$2.60M | -$2.09M | -$7.91M | -- |
| **Investing Cash Flow** | -- | -- | -- | $0 | $0 | $0 | -$4.0K | -- |
| Common Stock Issued | -- | $886K | $1.67M | -- | -- | -$18.26M | $18.35M | -- |
| **Financing Cash Flow** | $13.72M | $886K | $5.87M | $1.79M | $84K | $84K | $18.35M | $97K |
| **Net Change in Cash** | $7.99M | -$2.81M | $3.24M | -$2.92M | -$2.51M | -$2.01M | $10.43M | -$524K |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- |
| Return on Assets (ROA) | -705.4% | 1336.9% | -487.6% | 3.0% |
| Current Ratio | 0.49x | 0.11x | 0.12x | 1.00x |
| Quick Ratio | 0.44x | 0.00x | 0.12x | 0.60x |
| Operating Income Growth (YoY) | -117.5% | -- | -- | -- |
| **Net Income Growth (YoY)** | -193.4% | -- | -740.9% | -- |
| EPS Growth (YoY) | -105.1% | -- | -- | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -1995.8% | -- | -- | -- | -- | -- | -- | -- |
| Return on Assets (ROA) | -337.0% | -924.2% | -696.5% | -705.4% | 0.0% | -14.0% | 1225.6% | 1336.9% |
| Current Ratio | 2.75x | 0.54x | 0.99x | 0.49x | 0.90x | 1.12x | 1.43x | 0.11x |
| Quick Ratio | 2.50x | 0.47x | 0.94x | 0.44x | 0.72x | 0.92x | 1.21x | 0.00x |
| Debt to Equity | 0.47x | -- | -- | -- | -- | -- | -- | -- |
| Operating Income Growth (YoY) | -- | -- | -- | -- | -- | -102.8% | -- | -- |
| **Net Income Growth (YoY)** | -- | -- | -229.7% | -1883.7% | -- | -104.0% | -- | -- |
| EPS Growth (YoY) | -- | -- | -112.7% | -- | -- | -100.2% | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
